Investors with a lot of money to spend have taken a bullish stance on Novo Nordisk (NYSE:NVO).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NVO, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 22 uncommon options trades for Novo Nordisk.
This isn't normal.
The overall sentiment of these big-money traders is split between 45% bullish and 31%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $216,312, and 17 are calls, for a total amount of $1,024,460.
Projected Price Targets
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $115.0 to $175.0 for Novo Nordisk over the recent three months.
Volume & Open Interest Trends
In terms of liquidity and interest, the mean open interest for Novo Nordisk options trades today is 1509.47 with a total volume of 1,139.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Novo Nordisk's big money trades within a strike price range of $115.0 to $175.0 over the last 30 days.
Novo Nordisk Option Volume And Open Interest Over Last 30 Days
Biggest Options Spotted:
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
NVO | CALL | SWEEP | NEUTRAL | 03/21/25 | $12.15 | $12.15 | $12.15 | $155.00 | $172.4K | 81 | 0 |
NVO | CALL | TRADE | NEUTRAL | 01/16/26 | $23.7 | $22.9 | $23.25 | $150.00 | $160.4K | 1.7K | 27 |
NVO | CALL | TRADE | BEARISH | 09/20/24 | $3.05 | $2.82 | $2.89 | $160.00 | $101.1K | 7.0K | 201 |
NVO | CALL | TRADE | BEARISH | 01/16/26 | $23.35 | $23.0 | $23.0 | $150.00 | $80.5K | 1.7K | 99 |
NVO | CALL | TRADE | BEARISH | 01/16/26 | $23.65 | $23.25 | $23.25 | $150.00 | $58.1K | 1.7K | 2 |
About Novo Nordisk
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Having examined the options trading patterns of Novo Nordisk, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
Novo Nordisk's Current Market Status
Currently trading with a volume of 2,226,468, the NVO's price is down by -0.87%, now at $142.02.
RSI readings suggest the stock is currently may be approaching overbought.
Anticipated earnings release is in 56 days.
What The Experts Say On Novo Nordisk
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $160.0.
Maintaining their stance, an analyst from Argus Research continues to hold a Buy rating for Novo Nordisk, targeting a price of $160.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Novo Nordisk options trades with real-time alerts from Benzinga Pro.
